Bill SponsorBILLSPONSOR
Bill Sponsor
Politicians
Bills
Senate Bill 1594
117th Congress(2021-2022)
DEA Enforcement and Authority Act of 2021
Introduced
Introduced
Introduced in Senate on May 12, 2021
Overview
Text
Introduced in Senate 
May 12, 2021
Not Scanned for Linkage
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Introduced in Senate(May 12, 2021)
May 12, 2021
Not Scanned for Linkage
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Jump To
S. 1594 (Introduced-in-Senate)


117th CONGRESS
1st Session
S. 1594


To clarify the congressional intent behind the requirements relating to immediate suspension orders and corrective action plans under the Controlled Substances Act that were added by the Ensuring Patient Access and Effective Drug Enforcement Act of 2016.

IN THE SENATE OF THE UNITED STATES

May 12, 2021

Mr. Manchin introduced the following bill; which was read twice and referred to the Committee on the Judiciary

A BILL

To clarify the congressional intent behind the requirements relating to immediate suspension orders and corrective action plans under the Controlled Substances Act that were added by the Ensuring Patient Access and Effective Drug Enforcement Act of 2016.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “DEA Enforcement and Authority Act of 2021”.

SEC. 2. Denial, revocation, or suspension of controlled substances registration.

(a) Standard of review for immediate suspension orders.—Section 304(d)(2) of the Controlled Substances Act (21 U.S.C. 824(d)(2)) is amended by striking “a substantial likelihood of an immediate threat” and inserting “probable cause”.

(b) Opportunity To submit corrective action plan prior to revocation or suspension.—

(1) IN GENERAL.—Section 304(c) of the Controlled Substances Act (21 U.S.C. 824(c)) is amended—

(A) by striking paragraphs (2) through (5);

(B) by striking “(c)(1) Before” and inserting “(c) Before”; and

(C) by adding at the end the following: “The order to show cause shall contain a statement of the basis thereof and shall call upon the applicant or registrant to appear before the Attorney General at a time and place stated in the order, but in no event less than 30 days after the date of receipt of the order. Proceedings to deny, revoke, or suspend shall be conducted pursuant to this section in accordance with subchapter II of chapter 5 of title 5, United States Code. Such proceedings shall be independent of, and not in lieu of, criminal prosecutions or other proceedings under this title or any other law of the United States.”.

(2) APPLICABILITY TO PENDING CORRECTIVE ACTION PLANS.—The Attorney General shall not be required to review any corrective action plan submitted by an applicant or registrant under section 304(c)(2) of the Controlled Substances Act (21 U.S.C. 824(c)(2)), as in effect on the day before the date of enactment of this Act.